Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minimum effective dose of ropivacaine for ultrasound-guided median nerve block in pediatric trigger thumb surgery
ChiCTR2200062141Phase 4Recruiting
- Sponsor
- Children's Hospital of Chongqing Medical University
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ropivacaine in trigger finger, sponsored by Children's Hospital of Chongqing Medical University. Primary endpoints: 90% minimum effective concentration, 90% minimum effective volume and 6 more. Started Jul 2022; status: recruiting.
02
Drugs
ropivacaine
03
Conditions
trigger finger
Beyond the preview
Go deeper on ChiCTR2200062141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062141.